

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Clarence N. Ahlem, et al.  
Application No. : 10/602,330  
Filed : June 23, 2003  
Docket No. : 202.2D2  
5 Title : Pharmaceutical Compositions and Treatment Methods  
Examiner : Barbara P. Badio  
Group Art Unit : 1617  
Customer No. : 26551  
Confirmation No. : 9052

---

10

**INTERVIEW SUMMARY**

Commissioner for Patents  
P.O. Box 1450  
15 Alexandria, VA 22313-1450

Dear Sir,

Applicants submit this paper by electronic submission as required under 37 CFR  
20 § 1.133(b) after an interview with Examiner Badio on February 6, 2008 and a phone call  
discussion on February 29, 2008. On February 6, 2008, the undersigned and Dr. James  
Frincke, a co-inventor, discussed the pending claims and the outstanding rejection under  
35 USC § 112, first paragraph. Applicants discussed evidence of record in support of  
patentability, e.g., as indicated in Applicants' evidence of record, concerns that Examiner  
25 Badio had about the claimed subject matter and potential claim amendments. The  
undersigned sent amended claims with proposed claim amendments to Examiner Badio  
by facsimile and Examiner Badio commented on the proposed amendments.

Applicants greatly appreciate Examiner Badio's courtesy and willingness to  
discuss the claims with Applicants and her consideration of potentially allowable subject  
30 matter in this application.

Date: March 11, 2008

Hollis-Eden Pharmaceuticals, Inc.  
35 4435 Eastgate Mall, Suite 400  
San Diego, CA 92121

Respectfully submitted,  
/Daryl D. Muenchau/

Daryl D. Muenchau,  
Reg. No. 36,616  
Phone: 858-320-2569